In this episode, I speak with Detlev Parow, a former payer from one of Germany’s largest statutory health insurance funds. We unpack how German systems are managing access and affordability—sometimes in surprising ways.

Detlev shares why, in Germany, obesity drugs might not be the budgetary problem everyone assumes, why multiple indications don’t always mean lower prices, and how gene therapies are being handled through outcomes-based guarantees.

Along the way, we hear what it’s like to negotiate from “the dark side” and get a glimpse into a payer mindset shaped by pragmatism, experience, and a few unexpected views.

About The Payer Exchange

The Payer Exchange is a podcast where Omar Ali, Head of Payers at Verpora, sits down with payers from around the world to talk candidly about what’s shaping access, value, and decision-making in their markets.

The series covers a range of consistent themes across markets—such as horizon scanning, indication-based pricing, rare diseases, and system sustainability—while also highlighting country-specific dynamics. By asking the same core questions in each conversation, the podcast reveals both common pressures and contrasting approaches across healthcare systems.

The Payer Exchange is designed for professionals working in market access, pricing, policy, and strategy who want a deeper understanding of how payers are approaching the increasingly complex landscape of pharmaceutical innovation.

Disclaimer

This podcast is for educational and informational purposes only, and is not intended as legal or policy advice. All content is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Omar Ali, Verpora Limited.